- Motley Fool•10 hours ago
Is it time for Amgen to spend some of its cash stockpile? The big biotech's Q1 results say "yes."
- Market Realist•10 hours ago
On March 28, 2017, the FDA approved Regeneron (REGN) and Sanofi’s (SNY) Dupixent for the treatment of patients with moderate-to-severe eczema or atopic dermatitis (or AD).
- Business Insider•20 hours ago
One in 7 people in Nevada is living with diabetes, and the state is now pushing a new approach to tackle the cost of treatment
The state of Nevada is taking a new approach to tackling the rising price of prescription drugs...
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||85.01 - 86.15|
|52 Week Range||62.50 - 86.15|
|PE Ratio (TTM)||23.67|
|Dividend & Yield||3.35 (3.72%)|
|1y Target Est||N/A|